Table 1:
Clinical characteristics of the patients with N2 non-small-cell lung cancer before and after propensity score matching (%)
| Characteristics | Before PSM |
After PSM |
||||
|---|---|---|---|---|---|---|
| Preoperative radiotherapy group (n = 239) | Surgery alone group (n = 1151) | SMD | Preoperative radiotherapy group (n = 222) | Surgery alone group (n = 222) | SMD | |
| Age(years), n (%) | 0.422 | 0.028 | ||||
| ≤66 | 161 (67.4) | 540 (46.9) | 145 (65.3) | 142 (64.0) | ||
| >66 | 78 (32.6) | 611 (53.1) | 77 (34.7) | 80 (36.0) | ||
| Race, n (%) | 0.147 | 0.099 | ||||
| Black | 28 (11.7) | 102 (8.9) | 25 (11.2) | 24 (10.8) | ||
| White | 196 (82.0) | 939 (81.5) | 182 (82.0) | 177 (79.7) | ||
| Other | 15 (6.3) | 110 (9.6) | 15 (6.8) | 21 (9.5) | ||
| Gender, n (%) | 0.107 | 0.054 | ||||
| Male | 129 (54.0) | 560 (48.7) | 118 (53.2) | 112 (50.5) | ||
| Female | 110 (46.0) | 591 (51.3) | 104 (46.8) | 110 (49.5) | ||
| Grade, n (%) | 0.417 | 0.107 | ||||
| I | 5 (2.1) | 99 (8.6) | 5 (2.3) | 6 (2.7) | ||
| II | 83 (34.7) | 527 (45.8) | 83 (37.4) | 78 (35.1) | ||
| III | 149 (62.3) | 515 (44.7) | 133 (59.9) | 135 (60.8) | ||
| IV | 2 (0.8) | 9 (0.8) | 1 (0.4) | 3 (1.4) | ||
| Laterality, n (%) | 0.268 | 0.009 | ||||
| Left | 81 (33.9) | 540 (46.9) | 81 (36.5) | 82 (36.9) | ||
| Right | 158 (66.1) | 611 (53.1) | 141 (63.5) | 140 (63.0) | ||
| Histology, n (%) | 0.292 | 0.028 | ||||
| SCC | 97 (40.6) | 310 (26.9) | 85 (38.3) | 82 (36.9) | ||
| AC | 142 (59.4) | 841 (73.1) | 137 (61.7) | 140 (63.1) | ||
| Stage, n (%) | 0.187 | 0.014 | ||||
| IIIA | 210 (87.9) | 1074 (93.3) | 196 (88.3) | 195 (87.8) | ||
| IIIB | 29 (12.1) | 77 (6.7) | 26 (11.7) | 27 (12.2) | ||
| Tumour stage, n (%) | 0.333 | 0.063 | ||||
| T1 | 41 (17.2) | 276 (24.0) | 40 (18.0) | 45 (20.3) | ||
| T2 | 104 (43.5) | 594 (51.6) | 104 (46.8) | 101 (45.5) | ||
| T3 | 65 (27.2) | 204 (17.7) | 52 (23.4) | 49 (22.1) | ||
| T4 | 29 (12.1) | 77 (6.7) | 26 (11.7) | 27 (12.1) | ||
| LN examined, n (%) | 0.234 | 0.018 | ||||
| 0–9 | 111 (46.4) | 403 (35.0) | 98 (44.1) | 96 (43.2) | ||
| ≥10 | 128 (53.6) | 748 (65.0) | 124 (55.8) | 126 (56.8) | ||
| LN positivity, n (%) | 0.035 | 0.011 | ||||
| 0–5 | 185 (77.4) | 874 (75.9) | 172 (77.5) | 173 (77.9) | ||
| ≥6 | 54 (22.6) | 277 (24.1) | 50 (22.5) | 49 (22.1) | ||
AC: adenocarcinoma; LN: lymph node; PSM: propensity score matching; SCC: squamous cell carcinoma; SMD: standard mean difference.